Introduction
Depression is one of the most important non-motor symptoms of idiopathic Parkinson's disease (PD) . Depressed PD patients have reduced motor function and activities of daily living, exhibit more cognitive symptoms, and report lower quality of life than non-depressed patients. Clinical studies suggest that these consequences are reversible with adequate treatment, but depression is still underdiagnosed and undertreated in PD patients (1) (2) (3) . The incidence of depression in newly diagnosed PD patients was approximately two-fold higher compared to non-PD controls in a follow-up study based on the UK-General Practice Research Database (4) . A recent meta-analysis of studies assessing the prevalence of depression in PD patients reported that on average 35% of PD patients had depressive symptoms of clinical significance (5) , and a diagnosis of major depression according to DSM criteria could be established in 7 to 19 %.
In contrast to depression in non-PD patients, depression in PD-patients it is most likely caused by a combination of decreased levels of dopamine and acetylcholine, as well as serotonin (6) . The hypothesis that dopaminergic deficiency plays a role in depression of PD patients has stimulated some to hypothesize that treatment with dopamine agonists might be effective against depression in PD patients, in addition to alleviating motor symptoms. This notion was supported by some clinical trials (7) (8) , but a recent review considered the data inconclusive (1) . Interestingly, the dopamine agonist pramipexole to date is the only drug considered clinically useful for treatment of depressive symptoms in PD according to the Movement Disorders Society, whereas the efficacy of the widely used selective serotonin reuptake inhibitors (SSRIs) for PD depression is still controversial (9) . Specifically, a placebo-controlled trial of the SSRI citalopram in PD showed no statistically significant difference between the drug and placebo treatment (10) . However, a post hoc analysis found that approximately 70% of the patients in this trial suffered from Recurrent Brief Depression in accordance with ICD-10, which is more difficult to treat than major depression.
The PASIDA study is a population-based case-control study of PD patients in Denmark treated at ten neurological departments and first identified using the National Hospital Register between 1996 and 2009, for whom the diagnosis of idiopathic PD has been confirmed by an extensive medical record review. We investigated the use of antidepressant medications in the PASIDA study population as reported in the Danish National Prescription Registry after 1995. We hypothesized that PD patients treated with a dopamine agonist first would be less likely to start using antidepressant medications compared to patients receiving treatment with levodopa or MAO-B inhibitors as dopamine agonist use would supposedly reduce the necessity for additional pharmacological treatment of depression. (noradrenaline reuptake inhibitors, serotonin and noradrenaline reuptake inhibitors, and noradrenergic and specific serotonergic antidepressants).
Methods

From
Results
Among the 1,181 patients we followed, 438 patients were treated first with levodopa, and 468 and 275 with an agonist or a MAO-B inhibitor, respectively. 84, 73, and 69 per cent of the patients were older than 55 years at the onset of motor symptoms, and 58, 65, and 63 per cent of the patients were males in each of these treatment groups. Mean time on monotherapy was 1.8, 1.1, and 0.9 years for levodopa, agonist, and MAO-B inhibitor treated patients respectively. The mean follow-up time was 8.8, 7.1, and 9.3 years in the respective groups. No difference in the time to first prescription of an antidepressant was observed between patients who were first treated with levodopa, dopamine agonists, and MAO-B inhibitors (table 1). Separate analyses for each of the dopamine agonists pramipexole, ropinerole, and rotigotine also showed no effect on the subsequent use of antidepressants. Furthermore no differences were found in subgroups of patients defined by sex and age (data not shown).
Discussion
This study based on long-term follow-up of a relatively large number of PD patients was not able to show any difference in the use of anti-depressant medications using a Cox proportional hazards regression analysis. The most important limitation to this study is the fact that we are not able to assess the number of patients diagnosed with a clinically significant depression in our study population. The prescription patterns among the treating physicians might be influenced by other factors than depressive symptoms in the PD patients including the use of other medications such as PD medications with proposed antidepressant effects such as pramipexole or the use of MAO-B inhibitors, which are not recommended for use with SSRIs due to drug interaction problems.
Furthermore, SSRIs are prescribed for other conditions than depressions including neuropathic pain, anxiety disorders, and obsessive-compulsive disorders. Another important limitation is the fact that a second PD medication was added after a relatively short duration, making it difficult to assess the effect of a single PD medication alone on the need for an anti-depressant medication.
The strength of the study is that it reflects the current clinical practice regarding the use of PD medications and treatment of depression in PD patients in a field of research where previous clinical studies have been sponsored by a drug manufacturer and have not focused specifically on depression (1) . There is a need for future randomized controlled clinical trials to examine this hypothesis.
In conclusion, we were not able to confirm that treatment with a dopamine agonist delays time to antidepressant medication use compared to treatment with levodopa or MAO-B inhibitors in PD patients based on the PASIDA study population and the Danish National Prescription Registry. Figure S1 . Time from taking the first to taking a second drug Table 1 Demographic data, duration on PD drug monotherapy, and length of follow-up 
